CSPC Pharmaceutical’s SYS-6040 cleared to enter clinic in China for advanced solid tumors

March 21, 2025

CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials with SYS-6040 for advanced solid tumors.

BioWorld Science Regulatory Antibody-drug conjugate Immuno-oncology China NMPA

Today's news in brief

BioWorld

BioWorld briefs for March 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 24, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

Clinical trial fraud ends with guilty pleas

BioWorld

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...

Gene therapy efforts active, despite low Bluebird, 2seventy bids

BioWorld

Bristol Myers Squibb Co.’s decision this week to snag Bluebird Bio Inc. spinout 2seventy Bio Inc. for $102 million net – just weeks after investors bid $30...